US00445F1093 - Common Stock
ACERAGEN INC
NASDAQ:ACGN (8/21/2023, 7:21:21 PM)
After market: 0.395 +0.02 (+3.95%)0.38
-0.06 (-13.83%)
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Exton, Pennsylvania and currently employs 26 full-time employees. The firm is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
ACERAGEN INC
505 Eagleview Boulevard, Suite 212
Exton PENNSYLVANIA
P: 14843481600.0
Employees: 26
Website: https://www.aceragen.com/
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning!
Aceragen (ACGN) said Friday it will delist its shares from the Nasdaq.The company intends to voluntarily terminate the listing of its common stock by filing a Form 25 with the SEC on...
DURHAM, N.C. and EXTON, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that the Company intends to...
Here you can normally see the latest stock twits on ACGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: